SPECIAL NOTICE
66 -- VCB COVID-19 BD Max Supplies
- Notice Date
- 7/25/2020 9:30:54 AM
- Notice Type
- Justification
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- 257-NETWORK CONTRACT OFFICE 17 (36C257) ARLINGTON TX 76006 USA
- ZIP Code
- 76006
- Solicitation Number
- 36C25720AP3669
- Archive Date
- 09/23/2020
- Point of Contact
- robyn.nussbaum@va.gov, Robyn Nussbaum, Phone: 806-354-7830
- E-Mail Address
-
robyn.nussbaum@va.gov
(robyn.nussbaum@va.gov)
- Award Number
- 36C25720P1203
- Award Date
- 07/24/2020
- Awardee
- BECTON, DICKINSON AND COMPANY SPARKS 21152
- Award Amount
- 127890.24000000
- Description
- VHAPM Part 813.106 Simplified Acquisition Procedures: Soliciting from a Single Source Attachment 1: Single Source Justification for SAP under the SAT VHAPM Part 813.106 Page 1 of 1 Original Date: 08/30/17 Revision 02 Eff Date: 03/31/2020 DEPARTMENT OF VETERANS AFFAIRS Justification for Single Source Awards IAW FAR 13.106-1 For Over Micro-Purchase Threshold but Not Exceeding the SAT ($250K) Acquisition Plan Action ID: 36C257-20-AP-3669 Tracker Number: 2020-07-21T09:18:12 Agency: Department of Veterans Affairs (VA) Contracting Activity: Network Contracting Office 17 (NCO-17) 7201 W. Interstate 40, Ste 100 Amarillo, Texas 79106-2612 2237 Number: 740-20-4-2051-0371 Brief Description of Supplies/ Services required and the intended use/Estimated Amount: The HCC P&LMS laboratory requires additional reagents and controls to perform 2,000 SARS- CoV-2 tests on the existing BD MAX analyzer. Becton Dickinson & Co (BD) and BioGX have an FDA Emergency Use Authorization for this COVID-19 testing on the BD MAX platform. The estimated amount is $127,890.24 for one year. Unique characteristics that limit availability to only one source, with the reason no other supplies or services can be used: These reagents and controls are recently developed and not commercially available. They have been approved by the FDA under Emergency Use Authorization. As part of the agreement between BD and BioGX, BD is the exclusive distributor of the BioGX SARS-CoV-2 Reagents and Controls. Additionally, due to the nature of this requirement related to the current COVID-19 World-Wide Pandemic, BD is the only firm capable of providing the equipment described in Section 2 above without the Veteran s Health Administration experiencing unacceptable delays in fulfilling its requirements. As such, adverse patient outcomes would be unavoidable. Description of market research conducted and results or statement why it was not conducted: The BD MAX analyzer was purchased for the purpose of performing testing for COVID-19. With this analyzer, only BioGX has established reagents and controls to perform COVID-19 testing. BD and BioGX have an exclusive agreement and an Emergency Use Authorization through the FDA for this testing. A letter stating exclusive distribution rights was provided by BD. Contracting Officer's Certification: Purchase is approved in accordance with FAR13.106-1(b). I certify that the foregoing justification is accurate and complete to the best of my knowledge and belief. ____________________________ July 22, 2020 Robyn Nussbaum Date Contracting Officer
- Web Link
-
SAM.gov Permalink
(https://beta.sam.gov/opp/9cb665cd8639412996abc74145cb91b7/view)
- Record
- SN05733707-F 20200727/200725230129 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |